Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 13,940 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Depression, Anxiety
Interventions: Lumen Coached PST Intervention., Human Coached PST Intervention., Optional (delayed) Lumen Coached PST (Waitlist control).; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Total Knee Replacement, Genicular Nerve Block, Opioid Use
Interventions: Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Onychomycosis
Interventions: DBI-001, DBI-002, Aqueous Gel; Biological
Lead sponsor: DermBiont, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Encino, California • New Brighton, Minnesota • Portland, Oregon + 2 more

Conditions: Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions: Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI); Drug · Procedure · Device
Lead sponsor: Vascular Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Huntsville, Alabama • Phoenix, Arizona • Escondido, California + 1 more

Conditions: Non-Segmental Vitiligo
Interventions: ACT-777991, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Awareness During General Anesthesia
Interventions: Bispectral Index Monitor, Electronic MAC alert; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 100 Years
Enrollment: 22,185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Posttraumatic Stress Disorder
Interventions: Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD, Prevention and Relationship Education Program; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Overweight and Obesity, Cancer
Interventions: Devaluing energy-dense foods for cancer-control; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 60 Years
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Ischemic Stroke
Interventions: SOLITAIRE™ Device, MERCI® Device; Device
Lead sponsor: Medtronic Neurovascular Clinical Affairs; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Portland, Oregon • Tacoma, Washington

Conditions: Food Allergy
Interventions: Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more

Conditions: COVID-19
Interventions: Losartan; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Trigeminal Neuralgia
Interventions: Amifostine, CyberKnife stereotactic radiosurgery; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sexual Dysfunction, Major Depressive Disorder
Interventions: Vilazodone, Sertraline; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: HIV, Opiate Dependence
Interventions: Abstinence-reinforcing contingency management intervention, Performance Feedback intervention; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: The Bronx, New York

Conditions: COPE, Breast Cancer, First Line Therapy, Randomized Controlled Trial (RCT)
Interventions: Standard of Care (SOC), Intervention sessions; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postpartum Preeclampsia
Interventions: Early detection and management of postpartum preeclampsia bundle; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Vasectomy, NSAIDs, Post-operative Care
Interventions: Acetaminophen, ibuprofen, oxycodone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: Infections
Interventions: Prospective audit-and-feedback; Behavioral
Lead sponsor: Iowa City Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 21,842 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: ADHD
Interventions: Placebo, 200mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Hepatitis C
Interventions: TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Phantom Limb Pain After Amputation
Interventions: Targeted Brain Rehabilitation; Other
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions: ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment); Dietary Supplement · Other
Lead sponsor: Arbor Life Labs; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dry Eye Disease
Interventions: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee

Search by objective public record fields.

Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor(SPEAC) for Adults With Emotional Distress (Phase 2)

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

Intensive Multi-Couple Therapy for PTSD Versus Relationship Education in Military Couples

Devaluing Foods to Change Eating Behavior

SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Study of Open Label Losartan in COVID-19

A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment

Creating Opportunities For Personal Empowerment (COPE) In Women With Breast Cancer During First-Line Therapy: A Pilot Randomized Controlled Trial

Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study

Post-Vasectomy Pain Study

Improving Post-discharge Antimicrobial Use

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Prophylactic TBR on Phantom Limb Pain

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)